An observational study in Intracranial Aneurysm, Intracranial Aneurysm, Wide Neck Aneurysm, Large Neck Aneurysm Lesion and Aneurysmal Subarachnoid Hemorrhage, sponsored by Microvention-Terumo, Inc.. Recruiting at 1 site in Spain. Per ClinicalTrials.gov, last updated 2026-02-09.
Sponsored by Microvention-Terumo, Inc. (part of Terumo Corporation) · Observational
The MAESTRO registry is a post-market, single-arm, non-interventional, multicenter registry
Electronic platform to collect real-world clinical data, evaluate and periodically report safety and effectiveness of CE approved and commercially available Microvention devices used for the endovascular treatment of Intracranial aneurysms and acute ischemic stroke.
418 studies on the registry are indexed under Intracranial Aneurysm; 119 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 200 across 191 observational studies indexed under Intracranial Aneurysm.
Browse Intracranial Aneurysm studies →Microvention-Terumo, Inc. is the lead sponsor of 32 studies on the registry; 7 are open to participants now.
First submitted after Microvention-Terumo, Inc. became part of Terumo Corporation.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Note: For the purposes of this protocol, ancillary/accessory devices such as balloon catheters, carotid stent for extracranial stenosis and other access devices are not considered primary treatment devices. Further, devices used for rescue following attempt of a different primary treatment device are not considered initial primary treatment devices.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cohort 1 will focus on data collection on all Microvention Class III implantable device CE marked used in the treatment of intracranial aneurysms
Device: All Microvention Class III implantable device CE marked
Cohort 2 will focus on data collection on all Microvention Class III device CE marked used in the treatment of Acute Ischemic Stroke
Device: All Microvention Mechanical Thrombectomy Class III device CE marked
Endovascular treatment of ruptured or unruptured intracranial aneurysms with commercially available MicroVention implant devices.
Endovascular treatment of acute ischemic stroke with commercially available MicroVention devices.
Cohort 1: Proportion of aneurysms with complete occlusion
based on Raymond-Roy occlusion classification (RROC) evaluated by an independent Core laboratory
Time frame: 18 (±6) months
Cohort 2: Proportion of patients achieving final mTICI ≥ 2b revascularization
based on independent Corelab assessment
Time frame: Mechanical trombectomy Procedure
Plan to share: No — Confidential document. Only published data will be available
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Dec 2029, 60 months after the start.
Of 104 observational studies under Intracranial Aneurysm, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 145. This study's planned 60 months is above that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.